{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"66","value":"4130"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles 1-4 (21-day cycle):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nAfter 4 cycles, participants may have continued on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nMaintenance therapy (every 21 days):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nIf, as of 25 Oct 2012, the participant was in maintenance therapy and randomized to the experimental arm, the participant was eligible to continue with pemetrexed/LY2603618 therapy if the investigator deemed it was in the participant's best interest and the participant consented.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 2: Pemetrexed + Cisplatin + LY2603618"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Phase 2 participants who received at least 1 dose of LY2603618 and had samples collected for pharmacokinetic analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1/Day 2 - predose, immediately prior to the end of the LY2603618 infusion, and 2-6, 24-48, and 72-96 hours postdose","title":"Phase 2: Pharmacokinetic: Cmax (LY2603618)","type":"SECONDARY","unitOfMeasure":"ng/mL"}